Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify a stock or a cryptocurrency in the search bar to get a summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Palisade Bio Inc
PALICurrent price
4.02 USD
-0.06 USD (-1.47%)
Last closed
4.08 USD
Company
www.palisadebio.com
ISIN
US6963894026
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Capitalization
4 489 217 USD
Yield for 12 month
-54.58 %
1Y
3Y
5Y
10Y
15Y
PALI
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on focuses on developing therapeutics that protect the integrity of the intestinal barrier in the United States. The company's lead therapeutic candidate is PALI-2108, a prodrug PDE4 inhibitor, currently under pre-clinical development as a therapeutic for patients living with inflammatory bowel diseases, including ulcerative colitis and Crohn's disease (CD), as well as develops PALI-1908, an oral, selective PDE4 inhibitor prodrug that is locally bioactivated in the terminal ileum of CD patients, currently in the research stage. It has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; a license agreement with the Regents of the University of California; a co-development and distribution agreement with Newsoara Biopharma Co., Ltd; and a transformative strategic collaboration with Strand Life Sciences for advancing precision medicine for ulcerative colitis therapy. The company is based in Carlsbad, California. Address: 7750 El Camino Real, Carlsbad, CA, United States, 92009
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
33.75 USDP/E ratio
–Dividend Yield
–Current Year
+250 000 USD
Last Year
+250 000 USD
Current Quarter
–
Last Quarter
–
Current Year
+246 000 USD
Last Year
-167 000 USD
Current Quarter
-1 000 USD
Last Quarter
-1 000 USD
Key Figures PALI
1 year
3 years
5 years
10 years
EBITDA
-14 588 000 USD
Operating Margin TTM
PE Ratio
–
Return On Assets TTM
-58.53 %
PEG Ratio
–
Return On Equity TTM
-110.09 %
Wall Street Target Price
33.75 USD
Revenue TTM
–
Book Value
10.29 USD
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
–
Dividend Yield
–
Gross Profit TTM
–
Earnings per share
-18.57 USD
Diluted Eps TTM
-18.57 USD
Most Recent Quarter
II 2024
Quarterly Earnings Growth YOY
–
Profit Margin
–
Dividend Analytics PALI
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History PALI
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
–
Ex Dividend Date
–
Forward Annual Dividend Yield
–
Last Split Factor
1:15
Payout Ratio
–
Last Split Date
08.04.2024
Dividend Date
18.07.2019
Stock Valuation PALI
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
–
Forward PE
–
Enterprise Value Revenue
234.8894
Price Sales TTM
14.0311
Enterprise Value EBITDA
0.5714
Price Book MRQ
0.4513
Financials PALI
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators PALI
For 52 weeks
3.3 USD
14.4 USD
50 Day MA
3.86 USD
Shares Short Prior Month
60 221
200 Day MA
5.93 USD
Short Ratio
2.24
Shares Short
49 486
Short Percent
4.21 %
BeatStart